輝瑞稱其新型肺炎疫苗有效增加5至11歲兒童抗體
輝瑞(PFE.US)與BioNTech(BNTX.US)表示,兩企聯合開發的新型肺炎疫苗,於一項大型臨牀試驗中讓5至11歲兒童產生強烈抗體反應。
該試驗有2,268人蔘與,共注射兩次10微克劑量的疫苗,相當於成人劑量的三分之一,而產生的抗體水平與接受成人劑量的16至25歲青少年組的試驗結果相當,並有類似副作用。
輝瑞發言人指,計劃最早於本月向美國食品藥品管理局(FDA)申請緊急使用授權。該疫苗已獲得16歲及16歲以上人羣的全面批準,並獲得12至15歲青少年的緊急使用授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.